This study is a prospective, single-arm, exploratory clinical research aimed at evaluating the efficacy and safety of lucetamab in combination with leucovorin in the conversion therapy of locally advanced potentially resectable EGFR mutation-positive non-small cell lung cancer, providing more robust clinical evidence for the improvement of treatment modalities for EGFR-mutated locally advanced NSCLC. At the same time, it seeks to identify biomarkers that can predict the therapeutic effect of the combination of lucetamab and leucovorin, offering more precise guidance for the selection of clinical treatment plans and enabling patients to receive the optimal treatment regimen.
Sign the informed consent form
The age of the subjects is over 18 years old
Patients with non-small cell lung cancer (NSCLC) with EGFR mutation confirmed by pathology
Confirmed as locally advanced NSCLC (IIIA, IIIB, IIIC) by chest CT, PET-CT or/and EBUS, and MDT discussion concludes that immediate local surgery is not suitable
Allergy to Sacituzumab Tirumotecan or any of its excipients
Patients allergic to Limertinib or any of its excipients
Patients with a history of other primary tumors; patients with a history of allogeneic organ transplantation
Major surgery within 4 weeks before the first dose (excluding diagnostic biopsy)